 |
|
|
| |
SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
David Wyles1, Fred Poordad2, Stanley Wang3, Laurent Alric4, Franco Felizarta5, Paul Y Kwo6, Benedict Maliakkal7, Kosh Agarwal8, Tarek Hassanein9, Frank Weilert10, Samuel S Lee11, Ran Liu3, Chih-Wei Lin3, Teresa I Ng3, Federico Mensa3
1Denver Health Medical Center, Denver, CO, USA; 2The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Department of Internal Medicine and Digestive Diseases, CHU Purpan, UMR 152, IRD Toulouse 3 University, France; 5Private Practice, Bakersfield, California, USA; 6Indiana University School of Medicine, Indianapolis, IN, USA; 7University of California San Diego, La Jolla, CA, USA; 8Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 9Southern California GI and Liver Centers and Southern California Research Center, Coronado, CA, USA; 10Tawa Street Specialist Clinic, Hamilton, New Zealand; 11University of Calgary, Calgary, AB, Canada
|
| |
|
|
|
|
|
